E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Marine Drugs in the Management of Metabolic Diseases"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 30 June 2018

Special Issue Editor

Guest Editor
Dr. Graciliana Lopes

REQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal
Interests: marine drugs; drug discovery; Diabetes mellitus; oxidative stress; seaweed bioactive compounds; phlorotannins

Special Issue Information

Dear Colleagues,

Metabolic diseases consist of complex heterogeneous disorders caused by the breakdown of body homeostasis, which greatly affect individuals’ quality of life. Mainly due to significant changes in human lifestyle, such as sedentarism, excess calories and exponential growth of emotional stress, metabolic diseases have been the current target of public health and scientific concern.

Marine organisms are rich sources of bioactive compounds with diverse molecular structures and biological activities, which place them at the forefront as the most appealing sources of drug leads in the 21st century. In addition to constituting privileged targets of chemical and molecular studies, marine drugs have a privileged role in pharmaceutical bioprospecting, representing a new hope for the management of metabolic diseases.

In this Special Issue, we are seeking original and high quality research articles, as well as reviews, focused on marine drugs with potential for the pharmacological management of metabolic diseases, with emphasis on diabetes mellitus, dyslipidaemia and gut. We intend to highlight surveys concerning novel compounds from marine sources, with relevant prospects on metabolic diseases related processes.

Dr. Graciliana Lopes
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Metabolic diseases (Diabetes mellitus, Gut, Dyslipidaemia, Hypertension)
  • Mechanism of action
  • Compounds isolation and molecular modulation
  • Genetic modulation of mediators involved in metabolism homeostasis
  • Structure-activity relationship

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Deep Sea Water Improves Abnormalities in Lipid Metabolism through Lipolysis and Fatty Acid Oxidation in High-Fat Diet-Induced Obese Rats
Mar. Drugs 2017, 15(12), 386; doi:10.3390/md15120386
Received: 30 October 2017 / Revised: 29 November 2017 / Accepted: 5 December 2017 / Published: 11 December 2017
PDF Full-text (3022 KB) | HTML Full-text | XML Full-text
Deep sea water (DSW) is a natural marine resource that has been utilized for food, agriculture, cosmetics, and medicine. The aim of this study was to investigate whether DSW has beneficial lipid metabolic effects in an animal model. Our previous in vitro study
[...] Read more.
Deep sea water (DSW) is a natural marine resource that has been utilized for food, agriculture, cosmetics, and medicine. The aim of this study was to investigate whether DSW has beneficial lipid metabolic effects in an animal model. Our previous in vitro study indicated that DSW significantly decreased the intracellular triglyceride and glycerol-3-phosphate dehydrogenase activity in 3T3-L1 adipocytes. DSW also inhibited the gene levels of adipocyte differentiation, lipogenesis, and adipocytokines, and up-regulated gene levels of lipolysis and fatty acid oxidation. In the present study, the results showed that body weight, liver, adipose tissue, hepatic triglycerides and cholesterol, and serum parameters in the high-fat diet (HFD) + DSW groups were significantly lower compared to the HFD group. Moreover, the fecal output of total lipids, triglycerides, and cholesterol in the HFD + DSW groups was significantly higher than that of the HFD group. Regarding gene expression, DSW significantly increased the gene levels of lipolysis and fatty acid oxidation, and decreased the gene levels of adipocytokine in the adipose tissue of rats with HFD-induced obesity. These results indicate a potential molecular mechanism by which DSW can suppress obesity in rats with HFD-induced obesity through lipolysis and fatty acid oxidation. Full article
(This article belongs to the Special Issue Marine Drugs in the Management of Metabolic Diseases)

Figure 1a

Back to Top